Latest period
$1.45M
YoY change
+25.1%
5Y CAGR
+27.6%
Peak year (2014)
$5.39M
Latest annual
$1.96M
Stock-Based Compensation history chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: $1.96M
Stock-Based Compensation growth chart for SELLAS Life Sciences Group (SLS) from 2006 to 2025
Latest: +25.1%
Stock-Based Compensation history table for SELLAS Life Sciences Group (SLS) from 2006 to 2025
| 2025 | $1.96M | +25.1% | +$392.00K | ||
| 2024 | $1.56M | +12.5% | +$174.00K | ||
| 2023 | $1.39M | -19.5% | −$336.00K | ||
| 2022 | $1.73M | +70.7% | +$715.00K | ||
| 2021 | $1.01M | +74.9% | +$433.00K | ||
| 2020 | $578.00K | +0.9% | +$5.00K | ||
| 2019 | $573.00K | +45.1% | +$178.00K | ||
| 2018 | $395.00K | -87.5% | −$2.77M | ||
| 2017 | $3.17M | +40.0% | +$905.00K | ||
| 2016 | $2.26M | +17.2% | +$333.00K | ||
| 2015 | $1.93M | -64.2% | −$3.46M | ||
| 2014 | $5.39M | +112.9% | +$2.86M | ||
| 2013 | $2.53M | +81.5% | +$1.14M | ||
| 2012 | $1.39M | -53.5% | −$1.61M | ||
| 2011 | $3.00M | -31.3% | −$1.37M | ||
| 2010 | $4.37M | +4.0% | +$166.00K | ||
| 2009 | $4.20M | +9.9% | +$378.00K | ||
| 2008 | $3.82M | — | +$3.82M | ||
| 2007 | $0.00 | — | $0.00 | ||
| 2006 | $0.00 | — | — |
- 2025$1.96M+25.1%
- 2024$1.56M+12.5%
- 2023$1.39M-19.5%
- 2022$1.73M+70.7%
- 2021$1.01M+74.9%
- 2020$578.00K+0.9%
- 2019$573.00K+45.1%
- 2018$395.00K-87.5%
- 2017$3.17M+40.0%
- 2016$2.26M+17.2%
- 2015$1.93M-64.2%
- 2014$5.39M+112.9%
- 2013$2.53M+81.5%
- 2012$1.39M-53.5%
- 2011$3.00M-31.3%
- 2010$4.37M+4.0%
- 2009$4.20M+9.9%
- 2008$3.82M—
- 2007$0.00—
- 2006$0.00—
Stock-Based Compensation values are taken from SELLAS Life Sciences Group's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at SELLAS Life Sciences Group (SLS)
Stock-Based Compensation for SELLAS Life Sciences Group (SLS): headline value $1.45M · YoY +25.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, SELLAS Life Sciences Group (SLS) reported stock-based compensation of $1.96M – grew 25.1% year-over-year.
Across 2020–2025 (5 years), SELLAS Life Sciences Group stock-based compensation produced a CAGR of +27.6% – with mixed annual results across the window.
The highest annual stock-based compensation of $5.39M was reported in 2014. The lowest in the available history was $0.00 in 2006.
SELLAS Life Sciences Group Stock-Based Compensation by Year
SELLAS Life Sciences Group Stock-Based Compensation 2025: $1.96M
SELLAS Life Sciences Group posted stock-based compensation of $1.96M in 2025, grew 25.1% from 2024.
SELLAS Life Sciences Group Stock-Based Compensation 2024: $1.56M
In 2024, SELLAS Life Sciences Group reported stock-based compensation of $1.56M, grew 12.5% from 2023.
SELLAS Life Sciences Group Stock-Based Compensation 2023: $1.39M
SELLAS Life Sciences Group stock-based compensation in 2023 was $1.39M, declined 19.5% below 2022.
SELLAS Life Sciences Group Stock-Based Compensation 2022: $1.73M
2022's stock-based compensation for SELLAS Life Sciences Group came in at $1.73M, surged 70.7% from 2021.
SELLAS Life Sciences Group Stock-Based Compensation 2021: $1.01M
SELLAS Life Sciences Group stock-based compensation in 2021 was $1.01M.
See more financial history for SELLAS Life Sciences Group (SLS).
Sector peers by Stock-Based Compensation
Healthcare peers of SELLAS Life Sciences Group (SLS), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation